Albakri A (2018) Chemotherapy-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy Albakri A (2018) Chemotherapy-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy Albakri A (2018) Chemotherapy-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of

more »

... ographic diagnosis and the value of cardioprotection therapy Albakri A (2018) Chemotherapy-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy . Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: Current practice and prospects of prophylaxis. European Journal of Heart Failure 4: 235-242. 35. Buzdar AU (1978) Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer treatment reports 62: 1005-1008. 36. Villani F (1985) Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Medical Oncology 2: 93-97. 37. Verweij J (1988) A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Medical oncology and tumor pharmacotherapy 5: 159-163. 38. Marty M (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology 23: 4265-4274. Albakri A (2018) Chemotherapy-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy Albakri A (2018) Chemotherapy-induced cardiomyopathy: a review of literature on clinical status and meta-analysis of echocardiographic diagnosis and the value of cardioprotection therapy